|Protocol #||Sponsor||Protocol Title|
|A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 2/3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)|
Pancreas cancer remains a highly lethal disease. NGOC physicians work with multi-disciplinary teams of gastroenterologists, surgical oncologists and radiation oncologists to provide optimal treatment for patients with pancreas cancer. For patients with advanced disease, treatment with investigational protocols are offered whenever possible.